anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Twenty-two percent of deliveries in France are induced. In cases where labor is induced and cervix is unfavorable, cervical ripening prior oxytocin administration is advised in order to reduce the risk of cesarean delivery. Cervical ripening agents, pharmacological (prostaglandins) or mechanical are administered during 24 hours. After 24 hours, most women will be either delivered or in labor but 25% of women will require further induction of labor. For 16% of women who undergo cervical ripening, whatever the cervical ripening method, the cervix remains unchanged after 24 hours. The management of these women is not consensual and depends on the maternity unit where women are cared for. In some units, women are admitted into labor ward for induction of labor with oxytocin. Elsewhere cervical ripening is repeated in order to obtain a favorable cervix and to reduce the risk of caesarean delivery.

This study seeks to identify the most appropriate strategy for the management of women with an unfavorable cervix after 24 hours of cervical ripening, a strategy which would be associated with the lowest maternal and perinatal morbidity but also with the best maternal satisfaction. Because both strategies are practiced in France, the trial would compare: induction of labor with oxytocin and repeated cervical ripening. The policy of induction of labor with oxytocin, being the simpler strategy, would be acceptable if it did not lead to a substantially proportion of women with caesarean deliveries compared with a second cervical ripening. This multicenter non inferiority randomized trial will recruit women with an unfavorable cervix (bishop score ≤ 6) after 24 hours of cervical ripening (pharmacological or mechanical) and randomize them to either induction of labor with oxytocin or to a second cervical ripening with prostaglandins. The aim is to show that repeating cervical ripening is an unnecessary procedure. And more specifically that oxytocin administration is not associated with a higher caesarean delivery rate and that it reduces the time to delivery in comparison with cervical ripening with prostaglandins.
NEW MATERIAL:A compound expressed by the formula [either one of R1 and R2 is CH(CH3)OR (R is lower alkyl) and the other is vinyl or R1 and R2 together form CH(CH3)OR] and a salt thereof. EXAMPLE:3-Methoxyethyl-8-vinyl-deuteroporphyrin. USE:A photosensitizer for treating cancers by irradiation with laser, obtainable as a simple compound, and having improved photosensitizing action and easy availability of raw materials. PREPARATION:A salt or alkyl ester of protoporphyrin, e.g. protoporphyrin dimethyl ester, is alcoholized in an alcohol in the presence of an acid, e.g. hydrogen chloride, and de-esterified in the case of an ester. The resultant product is obtained as a mixture of substances alcoholized at the 3- or 8-position only and both the 3- and 8-positions. The mixture is then separated by silica gel column chromatography, etc. to afford the aimed compound expressed by the formula.
Crohn's disease (CD) is a type of inflammatory bowel disease (IBD) characterized by chronic inflammation in the digestive tract. The pathogenesis of IBD involves immunological, genetic and environmental factors. Currently there is no cure for Crohn's disease and available medical and surgical treatments are expensive and often associated with significant side effects. Anti-tumor necrosis factor alpha (anti-TNF-α) agents are widely used for treatment of Crohn's disease. Electrical neuromodulation is a new treatment approach of bioelectronic medicine, involving molecular medicine, neuroscience, and bioengineering. Multiple possible mechanisms have been proposed for electrical neuromodulation in GI diseases, including central, autonomic, and/or enteric mechanisms. Vagal tone is significantly blunted in IBD and is associated with high TNF- α levels. Animal and preliminary human studies have demonstrated that electrical vagal nerve stimulation (VNS), including non-invasive vagal stimulation (nVNS), exerts an anti-inflammatory effect by harnessing the cholinergic anti-inflammatory pathway. In healthy humans nVNS has been shown to decrease tumor necrosis factor-α levels. Invasive VNS has been shown to improve inflammation in preliminary studies in patients with Crohn's disease.

Adult patients with active Crohn's disease will be asked to self-administer transcutaneous vagal nerve stimulation three times per day for 16 weeks. Inflammatory laboratory markers will be compared for each patient against their baseline levels to determine if the intervention helps reduce inflammation cause by their Crohn's disease. Questionnaires will be administered to evaluation their symptoms, and quality of life over the 16 week treatment period.
Structural epilepsies display complex immune activation signatures. However, it is unclear which neuroinflammatory pathways drive pathobiology. Transcriptome studies of brain resections from mesial temporal lobe epilepsy (mTLE) patients revealed a dysregulation of transforming growth factor β, interferon α/β, and nuclear factor erythroid 2-related factor 2 pathways. Since these pathways are regulated by ubiquitin-specific proteases (USP), in particular USP15, we hypothesized that USP15 blockade may provide therapeutic relief in treatment-resistant epilepsies. For validation, transgenic mice which either constitutively or inducibly lack Usp15 gene expression underwent intrahippocampal kainate injections to induce mTLE. We show that the severity of status epilepticus is unaltered in mice constitutively lacking Usp15 compared to wild types. Cell death, reactive gliosis, and changes in the inflammatory transcriptome were pronounced at 4 days after kainate injection. However, these brain inflammation signatures did not differ between genotypes. Likewise, induced deletion of Usp15 in chronic epilepsy did not affect seizure generation, cell death, gliosis, or the transcriptome. Concordantly, siRNA-mediated knockdown of Usp15 in a microglial cell line did not impact inflammatory responses in the form of cytokine release. Our data show that a lack of USP15 is insufficient to modulate the expression of relevant neuroinflammatory pathways in an mTLE mouse model and do not support targeting USP15 as a therapeutic approach for pharmacoresistant epilepsy.
FIELD: medicine, pharmaceutics. ^ SUBSTANCE: invention relates to zinc-containing antidote of lethal and severe poisonings with carbon monoxide. Claimed antidote represents intramolecular tricyclic complex of triethanolamine with zinc salts of inorganic or organic acids (2, 8, 9-trihydrozincatrane) with ratio of triethanolamine to zinc salts being 1:1. Invention also relates to method of protection against poisoning by carbon monoxide by peroral introduction into organism of zinc-containing antidote in 5 vol. % ethanol in dose range 20-60 mg/kg of body weight. ^ EFFECT: prevention of lethal poisoning with carbon monoxide, higher efficiency and reducing acute toxicity of zinc-containing antidote. ^ 9 cl, 5 ex.
The intervention 'family supportive EOLC' was developed based on the international guidelines of family-centered care (25) with additional aspects of care and support. The investigators designed a separated single-bedded EOLC room for the infant and parents. Other family members, such as grandparents or siblings, were allowed to visit the infant and parents. The design of the room included the option for parents to stay comfortably on a sofa to relax and to play soothing music. Parents were encouraged to stay as long as they want and participate in basic care including physical contact with their infant. The nurses supported the parents in creating commemorative items such as a 'Yuan man' box with photos, baby handprint cards, footprint cards, a lock of hair and other precious memory items. A psychologist, in collaboration with our NICU, and a neonatologist supported the parents by individual interviews.
The cerebral oxymetry saturation was monitored continuously, using a non-invasive method. The cerebral saturation was monitored intraoperatively with near infrared spectroscopy (INVOS 4100; Somanetics Inc, Troy, MI). Data acquired from the device were automatically and continuously recorded in 10-second intervals throughout the anaesthesia. A lead for the cerebral saturation monitoring was placed on degreased skin on the patient's forehead, on the right side, some 1 cm over the eyebrow. The baseline value was determined before induction of anaesthesia. The following criteria were accepted as significant reduction of the cerebral oxygenation (saturation) value: reduction of the cerebral oxymetry by over 25% in relation to the baseline; the absolute value of cerebral oxymetry below 50%.
The control group will receive usual care, including standard lifestyle advices during consultation with the GP, midwife, obstetrician or at the child well being centre. Furthermore, the control group will receive 1 recipe for a healthy meal per week.
BACKGROUND: Adolescents living with obesity (AlwO) can have limited exercise capacity. Exercise capacity can be predicted by a 2-factor model comprising lung function and leg muscle function, but no study has looked at cycling leg muscle function and its contribution to cycling exercise capacity in AlwO.
METHODS: Twenty-two nonobese adolescents and 22 AlwO (BMI > 95 percentile) were studied. Anthropometry, body composition (dual-energy X-ray absorptiometry), spirometry, 30-s isokinetic work capacity, and maximal exercise (cycle ergometry) were measured.
RESULTS: AlwO had greater total body mass, lean body mass, and lean leg mass (LLM). Lung function trended higher in AlwO. Leg 30-s work did not differ in absolute terms or per allometrically scaled LLM. Peak oxygen consumption did not differ between the groups in absolute terms or as percent predicted values (79.59 ± 14.6 vs. 82.3 ± 11.2% predicted control versus ALwO) but was lower in AlwO when expressed per kg body mass, kg lean body mass, scaled lean body mass, and LLM. Peak oxygen consumption related to both lung function and 30-s work, with no observed group effect. 30-s leg work related to the scaled LLM, with a small group effect. There was some correlation between leg work and time spent in moderate to vigorous physical activity in AlwO (rs = 0.39, p = .07).
CONCLUSION: AlwO have larger LLM and preserved exercise capacity, when expressed as percentage of predicted, but not per allometrically scaled LLM. Increasing time spent in moderate to vigorous activity may benefit AlwO.
Takayasu arteritis (TA) and inflammatory bowel disease (IBD) are two distinct diseases; however, previous studies have reported many cases of IBD-TA coexistence. Additionally, the incidence of IBD in patients with TA is estimated to be significantly higher than the incidence in the general population. Therefore, the two diseases are anticipated to be linked. Mendelian randomization (MR) analysis assesses whether an exposure might causally affect an outcome by using genetic variants inherited randomly at conception, thereby reducing the impact of confounding and reverse causality. The present study aimed to investigate the potential causal relationship between TA and IBD using MR analysis. Two-sample MR analysis, in which TA and IBD were regarded as the exposure and outcome, respectively, was conducted to investigate whether the two diseases are causally related using the R TwoSampleMR package. Summary GWAS data of TA consisted of 516 Turkish cohorts and 462 controls, and 119 patients and 993 controls of European ancestry. Summary data of IBD was from a sub-study of the International Inflammatory Bowel Disease Genetics Consortium (IIBDGC) that comprised 31,665 cases and 33,977 controls of European ancestry. Additionally, separate MR analyses stratified by the two major subtypes of IBD, Crohn's disease (CD) and ulcerative colitis (UC), were performed. Various statistical tests, including the intercept of MR-Egger regression, funnel plots, Cochran's Q tests, and leave-one-out sensitivity analyses, were employed to assess the presence of heterogeneity and horizontal pleiotropy among single nucleotide polymorphisms (SNPs). In the primary analysis using the inverse-variance weighted (IVW) method, the risk of developing IBD for a patient with TA compared to a non-TA control increased 1.053 times (Odds Ratio (OR) = 1.053, P = 0.065). The MR-Egger method (OR = 1.025, P = 0.470) yielded results consistent with this null finding. However, both the weighted median method (OR = 1.038, P = 0.002) and the weighted mode method (OR = 1.051, P = 0.009) identified a significant harmful causal effect. The MR outcomes from separate subgroup analyses slightly diverged from those of IBD and TA. Specifically, for CD, three methods indicated that TA is a risk factor: IVW estimated the OR as 1.045 (P = 0.032), MR-Egger as 0.997 (P = 0.957), weighed median as 1.028 (P = 0.021), and weighted mode as 1.031 (P = 0.022), respectively. This study represents one of the initial investigations into the potential causal association between TA and IBD. With three MR methods, including the primary IVW approach, indicating a notable effect on TA on CD, our analysis findings offer some indication that TA could be a contributing risk factor for CD.
Six vaccinations of the WT-1 peptide (1.0 ml of emulsion) will be administered on weeks 0, 4, 6, 8, 10 \& 12. Vaccinations will be administered subcutaneously with sites rotated among extremities. Injection sites will be pre-stimulated with Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 \& -2 of each vaccination. Patients may self administer the Sargramostim (GM-CSF) if they have been appropriately instructed on SQ injection administration. Patients will keep a logbook noting the time \& placement of the injection. Note: during each vaccination, the Sargramostim (GM-CSF) \& the vaccine emulsion will be administered to the same anatomical site. This site will be marked by the patient or treating healthcare professional by a permanent marker pen. For patients who have a clinical, molecular, or immunologic response \& have not had disease progression, they may receive up to 6 more vaccinations administered approximately every month.
The incentive spirometry group will continue the 8-week training with Volumetric Triflo. Individuals will be expected to exhale normally and hold their breath for at least 3 seconds after taking as deep a breath as possible. In the first week after surgery, the individual will be asked to work with an incentive spirometry in 10 repetitions every hour when awake. The group also followed standard program which includes phases of chest physiotherapy (modified postural drainage and assisted coughing techniques) and early progressive mobilization (gradually increasing walking distance in the corridor depending on patient tolerance). Participants in both groups will continue aerobic exercise training in the clinic until the end of the 8th week after discharge. Aerobic exercise training includes a bicycle ergometer, two days a week, 20-30 minutes, and perceived effort in the range of 60-70% of the maximal heart rate, in the range of 4-6 according to the Modified Borg Scale.
The present invention discloses a traditional Chinese medicine plaster for treating asthma and a manufacturing method thereof. The plaster is composed of original medicine and substrates, wherein the original medicine is prepared from manual musk, biond magnolia flower, manchurian wildginger, rhizoma corydalis, gansui root, white mustard seed and ginger; the substrates are prepared from polyethyleneglycol, glycerol, ethylparaben and laurocapram. The present invention has the preparation method that extract volatilization oil of raw medicinal materials is covered by HP-beta-cyclodextrin, and is mixed with extract powder and the manual musk to manufacture an ointment; PEG6000, and a right amount of glycerol and ethylparaben are added with a right amount of laurocapram to manufacture the substrates; the ointment is added to the substrates which are stirred when the ointment is added for thoroughly even mixing; thus, the medicine warehouse type traditional Chinese medicine plaster is pressed through subpackaging. The product of the present invention has the advantages of accurate administration dosage, convenient use and good application dependence for patients. Besides, the plaster can be taken off or pasted at any time. Therefore, the present invention is particularly suitable for asthma patient administration for children.
PURPOSE:To obtain highly sensitive reagent having nonspecific agglutination by heating latex wherein styrene is polymerized without emulsifier with presulfate as a polymerization starting agent in alkaline treatment, sensitizing antibody or antigen on latex, and performing serum treatment. CONSTITUTION:Polystyrene having a sulfuric acid group at the end of a molecule chain is heated in alkaline treatment. Then the hydrolysis of all the sulfuric acid group is substantially and forcibly performed to obtain dissociative corboxyl group. Thus latex is stabilized. The antibody or (antigen) is sensitized on said latex particles, and treatment is performed by the serum containing said antibody (or antigen). The latex reagent manufactured in this method excellently eliminates the nonspecific agglutination reaction, and the measuring sensitivity is remarkably enhanced.
FIELD: food industry, medicine. SUBSTANCE: invention relates to the nutritive supplement - balsam that comprises the following components: ginger, black pepper, caraway, long pepper and inflorescences of the following plants: Saint-John's-wort, forest violet, centaury, colt's foot and also: white barley, summer wheat grains, caltrap, mirobalan hebula, thermopsis, gentian, nutmeg, raisin, sessurea and groundsel. All components are subjected for grinding at absolute moisture value from 10 to 14%. After grinding each component is taken by a single equal mass part with exception for ginger and black pepper that are taken in the amount 0.5 mas. p. of each and with exception for long pepper that is taken in the amount 0.3 mas. p. Bee honey is taken in the amount 3-5% of total mass of all indicated ground components. These components, with exception for bee honey, are mixed among them. Standard specimen of components mixture in the amount 100 g is poured with 2 l of distilled water at 30-45  o  C, bee honey is added and infused in darkness in hermetic container at temperature from +3 to +6  o  C for 48 h. Before using the prescribed dose is poured off, filtered through sieve with cells size from 0.2 to 0.7 mm. Taken dose is mixed with natural grape wine of type: Kabernet or Burgundy, or Isabella, or with other natural dark grape wine in the strength of dry wine about 10% by alcohol in the ratio of solution mass to the wine mass 1:5-1:10. Then fulleride oily solution or fulleride fatty solution is taken and one of these solutions is added to indicated an aqueous-vinous-component mixture in the amount of fulleride solution 1-3% to mass of indicated mixture. Sea-buckthorn or burdock, or pagoda-tree oil is used as the oil. Cod liver oil, badger fat, or steppe souslik fat is used as the fat. The fulleride content in oil is 30-60 mg/ml. The fulleride content in fat is 20-70 mg/ml. The latter total mixture is shaken and kept for 1 h, not less, at temperature about 25  o  C. EFFECT: enhanced effectiveness of supplement.
PCT No. PCT/CH93/00029 Sec. 371 Date Sep. 20, 1993 Sec. 102(e) Date Sep. 20, 1993 PCT Filed Feb. 3, 1993 PCT Pub. No. WO93/16190 PCT Pub. Date Aug. 19, 1993.An extract based on modified bacterial proteins includes a mixture of acid bacterial polyanions having a molecular weight in the range from 10,000 to 1,000,000 and an isoelectric point in the range from 2.5 to 5.5, and in which the added weights of the constituent amino acids amount to at least 50% of the extract. The preparation or this protein extract includes a cultivation of bacteria in an aqueous medium and then the alkaline extraction of this bacterial suspension and the purification of the protein extract. The alkaline extraction is carried out in the presence of a dilute aqueous source of OH- ions and at a stable pH in the range from 11 to 13, the decrease of this pH during the acid extraction not exceeding 0.4. The protein extract thus obtained can be used as an active ingredient in a pharmaceutical composition.
BACKGROUND: We aim to deal with the Hub-genes and signalling pathways connected with Sepsis-associated encephalopathy (SAE).
METHODS: The raw datasets were acquired from the Gene Expression Omnibus (GEO) database (GSE198861 and GSE167610). R software filtered the differentially expressed genes (DEGs) for hub genes exploited for Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. Hub genes were identified from the intersection of DEGs via protein-protein interaction (PPI) network. And the single-cell dataset (GSE101901) was used to authenticate where the hub genes express in hippocampus cells. Cell-cell interaction analysis and Gene Set Variation Analysis (GSVA) analysis of the whole transcriptome validated the interactions between hippocampal cells.
RESULTS: A total of 161 DEGs were revealed in GSE198861 and GSE167610 datasets. Biological function analysis showed that the DEGs were primarily involved in the phagosome pathway and significantly enriched. The PPI network extracted 10 Hub genes. The M2 Macrophage cell decreased significantly during the acute period, and the hub gene may play a role in this biological process. The hippocampal variation pathway was associated with the MAPK signaling pathway.
CONCLUSION: Hub genes (Pecam1, Cdh5, Fcgr, C1qa, Vwf, Vegfa, C1qb, C1qc, Fcgr4 and Fcgr2b) may paticipate in the biological process of SAE.
PURPOSE:To provide a cosmetic containing a specific polysaccharide existing in ginseng and having skin-activating effect, as an active component, and suitable for the promotion of beauty and health of the skin and the hair. CONSTITUTION:The polysaccharide used in the present cosmetic is a component of ginseng, e.g. Panax ginseng, Panax japonicum, Panax quinquefolium, Panax notoginseng, especially Panax ginseng, and has the following characteristics. (i) Activity, having skin-activating effect; (ii) solubility, soluble in water, hardly soluble in methanol, and insoluble in ethanol, ether, benzene, chloroform and acetone; (iii) pH, about 5.5 in 1% aqueous solution; (iv) decomposition temperature, about 218 deg.C; and (v) color reactions, develops light yellowish red color with a mixture of 2% aqueous solution of phenol and concentrated sulfuric acid, and positive to the silver mirror reaction and Fehling's reagent. The polysaccharide is compounded to a cosmetic in an amount of 0.001-3wt%, especially 0.01-0.5wt% in the case of soap. A cosmetic having excellent beautifying effect can be prepared by this process.
Wait List Control subjects received Tele-PTM after completing the 6-month questionnaires. Participants assigned to Wait List Control were instructed that they could receive any available tinnitus services, and that they would receive Tele-PTM following completion of the 3- and 6-month questionnaires.
One single administration of study medication (IPN10200, Dysport or placebo) will be injected in a dose-escalation manner. Dose-escalation will include several cohorts.
The usual initial dose of furosemide for hypertension is 80 mg, usually divided into 40 mg twice a day. Dosage should then be adjusted according to response. If response is not satisfactory, add other antihypertensive agents.

Changes in blood pressure must be carefully monitored when furosemide is used with other antihypertensive drugs, especially during initial therapy. To prevent excessive drop in blood pressure, the dosage of other agents should be reduced by at least 50 percent when furosemide is added to the regimen. As the blood pressure falls under the potentiating effect of furosemide, a further reduction in dosage or even discontinuation of other antihypertensive drugs may be necessary.